MAB689-100

antibody from R&D Systems

Targeting: TNFRSF18 AITR, CD357, GITR

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Flow cytometry (Data presented on provider website)

Blocking/Neutralizing (Data presented on provider website)

Antibody Data

Product number

MAB689-100

Provider

R&D Systems

Product name

Human GITR/TNFRSF18 Antibody

Antibody type

Monoclonal

Description

Protein A or G purified from hybridoma culture supernatant. Detects human GITR in direct ELISAs and Western blots. Does not cross-react with recombinant human (rh) 4-1BB, recombinant mouse (rm) 4-1BB, rhCD27, rmCD27, rhCD30, rmCD30, rhCD40, rmCD40, rhDR3, rhDR6, rhEDAR, rmEDAR, rhFas, rmFAS, rmGITR, rhHVEM, rhLymphotoxin R beta , rmLymphotoxin R beta , rhNGF R, rhOPG, rmOPG, rhRANK, rmRANK, rhTAJ, rhTNF RI, rmTNF RI, rhTNF RII, or rmTNF RII.

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Antigen sequence

Q9Y5U5


Isotype

IgG

Antibody clone number

110416

Vial size

100 ug

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.

Lee F, Luevano M, Veys P, Yong K, Madrigal A, Shaw BE, Saudemont A
PloS one 2014;9(7):e103254

---

Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Schmiedel BJ, Werner A, Steinbacher J, Nuebling T, Buechele C, Grosse-Hovest L, Salih HR
Molecular therapy : the journal of the American Society of Gene Therapy 2013 Apr;21(4):877-86

---

CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma.

Mandapathil M, Szczepanski M, Harasymczuk M, Ren J, Cheng D, Jackson EK, Gorelik E, Johnson J, Lang S, Whiteside TL
Oncoimmunology 2012 Aug 1;1(5):659-669

---

Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1.

Savage ND, de Boer T, Walburg KV, Joosten SA, van Meijgaarden K, Geluk A, Ottenhoff TH
Journal of immunology (Baltimore, Md. : 1950) 2008 Aug 1;181(3):2220-6

---

Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions.

Baltz KM, Krusch M, Bringmann A, Brossart P, Mayer F, Kloss M, Baessler T, Kumbier I, Peterfi A, Kupka S, Kroeber S, Menzel D, Radsak MP, Rammensee HG, Salih HR
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007 Aug;21(10):2442-54

---

Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function.

Godfrey WR, Spoden DJ, Ge YG, Baker SR, Liu B, Levine BL, June CH, Blazar BR, Porter SB
Blood 2005 Jan 15;105(2):750-8

---

Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression.

Birebent B, Lorho R, Lechartier H, de Guibert S, Alizadeh M, Vu N, Beauplet A, Robillard N, Semana G
European journal of immunology 2004 Dec;34(12):3485-96